1. Home
  2. DH vs RIGL Comparison

DH vs RIGL Comparison

Compare DH & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DH
  • RIGL
  • Stock Information
  • Founded
  • DH 2011
  • RIGL 1996
  • Country
  • DH United States
  • RIGL United States
  • Employees
  • DH N/A
  • RIGL N/A
  • Industry
  • DH Computer Software: Prepackaged Software
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • DH Technology
  • RIGL Health Care
  • Exchange
  • DH Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • DH 280.0M
  • RIGL 335.5M
  • IPO Year
  • DH 2021
  • RIGL 2000
  • Fundamental
  • Price
  • DH $3.27
  • RIGL $20.15
  • Analyst Decision
  • DH Hold
  • RIGL Buy
  • Analyst Count
  • DH 10
  • RIGL 5
  • Target Price
  • DH $5.10
  • RIGL $36.40
  • AVG Volume (30 Days)
  • DH 775.4K
  • RIGL 240.6K
  • Earning Date
  • DH 05-08-2025
  • RIGL 05-06-2025
  • Dividend Yield
  • DH N/A
  • RIGL N/A
  • EPS Growth
  • DH N/A
  • RIGL N/A
  • EPS
  • DH N/A
  • RIGL 2.08
  • Revenue
  • DH $247,913,000.00
  • RIGL $203,077,000.00
  • Revenue This Year
  • DH N/A
  • RIGL $16.75
  • Revenue Next Year
  • DH $1.91
  • RIGL $13.74
  • P/E Ratio
  • DH N/A
  • RIGL $9.21
  • Revenue Growth
  • DH N/A
  • RIGL 70.16
  • 52 Week Low
  • DH $2.15
  • RIGL $7.48
  • 52 Week High
  • DH $6.27
  • RIGL $29.82
  • Technical
  • Relative Strength Index (RSI)
  • DH 56.19
  • RIGL 56.73
  • Support Level
  • DH $3.20
  • RIGL $18.63
  • Resistance Level
  • DH $3.44
  • RIGL $19.91
  • Average True Range (ATR)
  • DH 0.15
  • RIGL 1.09
  • MACD
  • DH -0.01
  • RIGL 0.00
  • Stochastic Oscillator
  • DH 36.36
  • RIGL 67.93

About DH Definitive Healthcare Corp.

Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: